E-business como herramienta para el mejoramiento de la gestión comercial en empresas industriales de Buenaventura

Although it is known that companies today have much more capacity for adaptation, 2020 devastated the labor market, a difficult year for the vast majority of companies in the world because they experienced a considerable drop in their income, both due to changes in consumption patterns as well as the sanitary restrictions implemented by governments. For this reason; The SENNOVA program and its Human Entrepreneurship research hotbed of the Nautical Fishing Center carried out this research work in order to contribute to the participation in the markets of SMEs in the industrial sector of Buenaventura.The companies object of the study were SMEs established in Buenaventura, belonging to the industrial sector, 434 registered companies complied with the profiling of the project. According to sample calculation, 26 SMEs were selected, collecting information through field work, applying an information collection instrument, allowing to know the current situation of SMEs registered in the Chamber of Commerce and identifying needs that impeded their growth. Once the information was collected, the analysis and decision-making process was carried out, as a result, 6 companies in the sector with low market participation were evidenced to intervene. Having identified the needs in each of the organizations, an E-business tool was acquired to generate optimization and efficiency in the processes that were carried out in them; This process was accompanied by a digital marketing specialist to display them in the market and attract a much wider audience. Allowing each of them today to have their social networks (Facebook, Instagram), a website compatible with computers and mobiles, advertising pieces, Chat Bots connected to WhatsApp to serve their customers 24/7, automating the responses required by their publicSi bien es sabido las empresas hoy en día tienen mucha más capacidad para la adaptación, el 2020 arrasó con el mercado laboral, año difícil para la gran mayoría de compañías del mundo porque experimentaron una considerable caída en sus ingresos, tanto por los cambios en los patrones de consumo como por las restricciones sanitarias implementadas por los gobiernos. Por esta razón; el programa SENNOVA y su semillero de investigación Emprendimiento Humano del Centro Náutico Pesquero realizó este trabajo investigativo con el fin de contribuir en la participación en los mercados de las pymes del sector industrial de Buenaventura.Las empresas objeto del estudio fueron pymes establecidas en Buenaventura, pertenecientes al sector industrial, 434 empresas registradas cumplieron con el perfilamiento del proyecto. De acuerdo al cálculo de la muestra; se seleccionaron 26 pymes, recopilando información a través de un trabajo de campo, aplicando un instrumento de recolección de información, permitiendo conocer la situación actual de las pymes registradas en la Cámara de Comercio e identificando necesidades que impedían el crecimiento de ellas. Una vez recopilada la información se realizó el proceso de análisis y toma de decisiones, como resultado se evidenciaron 6 empresas del sector con baja participación en el mercado para intervenir. Identificadas las necesidades en cada una de las organizaciones, se adquirió una herramienta E-business para generar optimización y eficiencia en los procesos que se llevaban a cabo en ellas; este proceso contó con acompañamiento de un especialista en marketing digital para visualizarlas en el mercado y atraer a un público mucho más amplio. Permitiendo que cada una de ellas hoy en día tengan sus redes sociales (Facebook, Instagram), sitio web compatible con ordenadores y móviles, piezas publicitarias, Chat Bots conectado a WhatsApp para atender a sus clientes 24/7, automatizando las respuestas requeridas por su públic

Innovación empresarial : nueva era de las agroempresas con gestión tecnológica

Este libro aborda la contextualización de las empresas del sector agrícola del occidente del Huila, desde un diagnóstico empresarial, el diseño de estrategias administrativas, contables y de mercadeo, hasta la innovación con desarrollo tecnológico aplicado a este sector.This book addresses the contextualization of companies in the agricultural sector in western Huila, from a business diagnosis, the design of administrative, accounting and marketing strategies, to innovation with technological development applied to this sector.Estrategias empresariales para el sector cafetero -- Innovación empresarial y sistema contable aplicado en la producción agrícola y pecuaria de la granja Juan Bosco -- Revisión bibliográfica para el desarrollo de productos electrónicos cumpliendo con estándares internacionales -- Evaluación de la eficiencia de un biofiltro para el tratamiento de aguas residuales del Café -- Fortalecimiento empresarial cafetero: una mirada hacia el cambio generacional, nuevos desafíos de responsabilidad social y liderazgo organizacional en el occidente del Huila -- Hábitos de consumo, mercado e importancia del café en el municipio de La Plata, Huila.na146 página

Global variations in diabetes mellitus based on fasting glucose and haemogloblin A1c

Fasting plasma glucose (FPG) and haemoglobin A1c (HbA1c) are both used to diagnose diabetes, but may identify different people as having diabetes. We used data from 117 population-based studies and quantified, in different world regions, the prevalence of diagnosed diabetes, and whether those who were previously undiagnosed and detected as having diabetes in survey screening had elevated FPG, HbA1c, or both. We developed prediction equations for estimating the probability that a person without previously diagnosed diabetes, and at a specific level of FPG, had elevated HbA1c, and vice versa. The age-standardised proportion of diabetes that was previously undiagnosed, and detected in survey screening, ranged from 30% in the high-income western region to 66% in south Asia. Among those with screen-detected diabetes with either test, the agestandardised proportion who had elevated levels of both FPG and HbA1c was 29-39% across regions; the remainder had discordant elevation of FPG or HbA1c. In most low- and middle-income regions, isolated elevated HbA1c more common than isolated elevated FPG. In these regions, the use of FPG alone may delay diabetes diagnosis and underestimate diabetes prevalence. Our prediction equations help allocate finite resources for measuring HbA1c to reduce the global gap in diabetes diagnosis and surveillance.peer-reviewe

Memorias de la semana de la Facultad de Educación / VI Semana: Investigaciones educativas y pedagógicas.

El presente libro, publicado en la Editorial de la Corporación Universitaria Minuto de Dios – UNIMINUTO, reúne las memorias de la VI Semana de la Facultad de Educación – FEDU “Investigaciones Educativas y Pedagógicas”, evento que se realiza cada año con el fin de intercambiar experiencias académicas, culturales y deportivas entre los estudiantes y profesores de la Facultad, con la participación de otras Universidades interesadas en compartir sus experiencias en el campo de la investigación, la cultura y el deporte. La temática para la VI Semana de la FEDU en 2016 estuvo relacionada con la investigación en torno a la educación y la pedagogía, de tal forma que los profesores y los estudiantes tuvieron la oportunidad de intercambiar experiencias desarrolladas en los proyectos y en los semilleros de investigación; además, los estudiantes y los egresados tuvieron la oportunidad de presentar los resultados de sus trabajos de grado y otros estudios productos de investigación

Global variation in diabetes diagnosis and prevalence based on fasting glucose and hemoglobin A1c

International audienceAbstract Fasting plasma glucose (FPG) and hemoglobin A1c (HbA1c) are both used to diagnose diabetes, but these measurements can identify different people as having diabetes. We used data from 117 population-based studies and quantified, in different world regions, the prevalence of diagnosed diabetes, and whether those who were previously undiagnosed and detected as having diabetes in survey screening, had elevated FPG, HbA1c or both. We developed prediction equations for estimating the probability that a person without previously diagnosed diabetes, and at a specific level of FPG, had elevated HbA1c, and vice versa. The age-standardized proportion of diabetes that was previously undiagnosed and detected in survey screening ranged from 30% in the high-income western region to 66% in south Asia. Among those with screen-detected diabetes with either test, the age-standardized proportion who had elevated levels of both FPG and HbA1c was 29–39% across regions; the remainder had discordant elevation of FPG or HbA1c. In most low- and middle-income regions, isolated elevated HbA1c was more common than isolated elevated FPG. In these regions, the use of FPG alone may delay diabetes diagnosis and underestimate diabetes prevalence. Our prediction equations help allocate finite resources for measuring HbA1c to reduce the global shortfall in diabetes diagnosis and surveillance

Global variation in diabetes diagnosis and prevalence based on fasting glucose and hemoglobin A1c

: Fasting plasma glucose (FPG) and hemoglobin A1c (HbA1c) are both used to diagnose diabetes, but these measurements can identify different people as having diabetes. We used data from 117 population-based studies and quantified, in different world regions, the prevalence of diagnosed diabetes, and whether those who were previously undiagnosed and detected as having diabetes in survey screening, had elevated FPG, HbA1c or both. We developed prediction equations for estimating the probability that a person without previously diagnosed diabetes, and at a specific level of FPG, had elevated HbA1c, and vice versa. The age-standardized proportion of diabetes that was previously undiagnosed and detected in survey screening ranged from 30% in the high-income western region to 66% in south Asia. Among those with screen-detected diabetes with either test, the age-standardized proportion who had elevated levels of both FPG and HbA1c was 29-39% across regions; the remainder had discordant elevation of FPG or HbA1c. In most low- and middle-income regions, isolated elevated HbA1c was more common than isolated elevated FPG. In these regions, the use of FPG alone may delay diabetes diagnosis and underestimate diabetes prevalence. Our prediction equations help allocate finite resources for measuring HbA1c to reduce the global shortfall in diabetes diagnosis and surveillance

Diminishing benefits of urban living for children and adolescents’ growth and development

Optimal growth and development in childhood and adolescence is crucial for lifelong health and well-being1–6. Here we used data from 2,325 population-based studies, with measurements of height and weight from 71 million participants, to report the height and body-mass index (BMI) of children and adolescents aged 5–19 years on the basis of rural and urban place of residence in 200 countries and territories from 1990 to 2020. In 1990, children and adolescents residing in cities were taller than their rural counterparts in all but a few high-income countries. By 2020, the urban height advantage became smaller in most countries, and in many high-income western countries it reversed into a small urban-based disadvantage. The exception was for boys in most countries in sub-Saharan Africa and in some countries in Oceania, south Asia and the region of central Asia, Middle East and north Africa. In these countries, successive cohorts of boys from rural places either did not gain height or possibly became shorter, and hence fell further behind their urban peers. The difference between the age-standardized mean BMI of children in urban and rural areas was <1.1 kg m–2 in the vast majority of countries. Within this small range, BMI increased slightly more in cities than in rural areas, except in south Asia, sub-Saharan Africa and some countries in central and eastern Europe. Our results show that in much of the world, the growth and developmental advantages of living in cities have diminished in the twenty-first century, whereas in much of sub-Saharan Africa they have amplified

GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19

Data availability: Downloadable summary data are available through the GenOMICC data site (https://genomicc.org/data). Summary statistics are available, but without the 23andMe summary statistics, except for the 10,000 most significant hits, for which full summary statistics are available. The full GWAS summary statistics for the 23andMe discovery dataset will be made available through 23andMe to qualified researchers under an agreement with 23andMe that protects the privacy of the 23andMe participants. For further information and to apply for access to the data, see the 23andMe website (https://research.23andMe.com/dataset-access/). All individual-level genotype and whole-genome sequencing data (for both academic and commercial uses) can be accessed through the UKRI/HDR UK Outbreak Data Analysis Platform (https://odap.ac.uk). A restricted dataset for a subset of GenOMICC participants is also available through the Genomics England data service. Monocyte RNA-seq data are available under the title ‘Monocyte gene expression data’ within the Oxford University Research Archives (https://doi.org/10.5287/ora-ko7q2nq66). Sequencing data will be made freely available to organizations and researchers to conduct research in accordance with the UK Policy Framework for Health and Social Care Research through a data access agreement. Sequencing data have been deposited at the European Genome–Phenome Archive (EGA), which is hosted by the EBI and the CRG, under accession number EGAS00001007111.Extended data figures and tables are available online at https://www.nature.com/articles/s41586-023-06034-3#Sec21 .Supplementary information is available online at https://www.nature.com/articles/s41586-023-06034-3#Sec22 .Code availability: Code to calculate the imputation of P values on the basis of SNPs in linkage disequilibrium is available at GitHub (https://github.com/baillielab/GenOMICC_GWAS).Acknowledgements: We thank the members of the Banco Nacional de ADN and the GRA@CE cohort group; and the research participants and employees of 23andMe for making this work possible. A full list of contributors who have provided data that were collated in the HGI project, including previous iterations, is available online (https://www.covid19hg.org/acknowledgements).Change history: 11 July 2023: A Correction to this paper has been published at: https://doi.org/10.1038/s41586-023-06383-z. -- In the version of this article initially published, the name of Ana Margarita Baldión-Elorza, of the SCOURGE Consortium, appeared incorrectly (as Ana María Baldion) and has now been amended in the HTML and PDF versions of the article.Copyright © The Author(s) 2023, Critical illness in COVID-19 is an extreme and clinically homogeneous disease phenotype that we have previously shown1 to be highly efficient for discovery of genetic associations2. Despite the advanced stage of illness at presentation, we have shown that host genetics in patients who are critically ill with COVID-19 can identify immunomodulatory therapies with strong beneficial effects in this group3. Here we analyse 24,202 cases of COVID-19 with critical illness comprising a combination of microarray genotype and whole-genome sequencing data from cases of critical illness in the international GenOMICC (11,440 cases) study, combined with other studies recruiting hospitalized patients with a strong focus on severe and critical disease: ISARIC4C (676 cases) and the SCOURGE consortium (5,934 cases). To put these results in the context of existing work, we conduct a meta-analysis of the new GenOMICC genome-wide association study (GWAS) results with previously published data. We find 49 genome-wide significant associations, of which 16 have not been reported previously. To investigate the therapeutic implications of these findings, we infer the structural consequences of protein-coding variants, and combine our GWAS results with gene expression data using a monocyte transcriptome-wide association study (TWAS) model, as well as gene and protein expression using Mendelian randomization. We identify potentially druggable targets in multiple systems, including inflammatory signalling (JAK1), monocyte–macrophage activation and endothelial permeability (PDE4A), immunometabolism (SLC2A5 and AK5), and host factors required for viral entry and replication (TMPRSS2 and RAB2A).GenOMICC was funded by Sepsis Research (the Fiona Elizabeth Agnew Trust), the Intensive Care Society, a Wellcome Trust Senior Research Fellowship (to J.K.B., 223164/Z/21/Z), the Department of Health and Social Care (DHSC), Illumina, LifeArc, the Medical Research Council, UKRI, a BBSRC Institute Program Support Grant to the Roslin Institute (BBS/E/D/20002172, BBS/E/D/10002070 and BBS/E/D/30002275) and UKRI grants MC_PC_20004, MC_PC_19025, MC_PC_1905 and MRNO2995X/1. A.D.B. acknowledges funding from the Wellcome PhD training fellowship for clinicians (204979/Z/16/Z), the Edinburgh Clinical Academic Track (ECAT) programme. This research is supported in part by the Data and Connectivity National Core Study, led by Health Data Research UK in partnership with the Office for National Statistics and funded by UK Research and Innovation (grant MC_PC_20029). Laboratory work was funded by a Wellcome Intermediate Clinical Fellowship to B.F. (201488/Z/16/Z). We acknowledge the staff at NHS Digital, Public Health England and the Intensive Care National Audit and Research Centre who provided clinical data on the participants; and the National Institute for Healthcare Research Clinical Research Network (NIHR CRN) and the Chief Scientist’s Office (Scotland), who facilitate recruitment into research studies in NHS hospitals, and to the global ISARIC and InFACT consortia. GenOMICC genotype controls were obtained using UK Biobank Resource under project 788 funded by Roslin Institute Strategic Programme Grants from the BBSRC (BBS/E/D/10002070 and BBS/E/D/30002275) and Health Data Research UK (HDR-9004 and HDR-9003). UK Biobank data were used in the GSMR analyses presented here under project 66982. The UK Biobank was established by the Wellcome Trust medical charity, Medical Research Council, Department of Health, Scottish Government and the Northwest Regional Development Agency. It has also had funding from the Welsh Assembly Government, British Heart Foundation and Diabetes UK. The work of L.K. was supported by an RCUK Innovation Fellowship from the National Productivity Investment Fund (MR/R026408/1). J.Y. is supported by the Westlake Education Foundation. SCOURGE is funded by the Instituto de Salud Carlos III (COV20_00622 to A.C., PI20/00876 to C.F.), European Union (ERDF) ‘A way of making Europe’, Fundación Amancio Ortega, Banco de Santander (to A.C.), Cabildo Insular de Tenerife (CGIEU0000219140 ‘Apuestas científicas del ITER para colaborar en la lucha contra la COVID-19’ to C.F.) and Fundación Canaria Instituto de Investigación Sanitaria de Canarias (PIFIISC20/57 to C.F.). We also acknowledge the contribution of the Centro National de Genotipado (CEGEN) and Centro de Supercomputación de Galicia (CESGA) for funding this project by providing supercomputing infrastructures. A.D.L. is a recipient of fellowships from the National Council for Scientific and Technological Development (CNPq)-Brazil (309173/2019-1 and 201527/2020-0)